Skip to main content
. Author manuscript; available in PMC: 2022 Jul 1.
Published in final edited form as: Clin Pharmacol Ther. 2021 Mar 11;110(1):82–97. doi: 10.1002/cpt.2166

Table 3.

Summary of edits and changes made as alleles were transitioned into the PharmVar database in September 2019.

Reason Change SNVs and Affected Alleles
Standardization Intronic SNVs were removed 12917A>T (*1D, *4C); 14593C>G (*1C); 15582C>T (*1C, *13B, *15A+B); 15837C>T (*28); 17897C>T (*18); 18273G>A (*11B, *12, *13A+B, *14, *15B, *17A+B, *18, *19, *20, *21, *27, *28, *38); 18627G>A (*18, *28); 21563C>T (*9, *13A+B, *19, *38).
rs4803419 was significantly associated with increased plasma efavirenz exposure in GWAS studies; however, this SNV was not consistently genotyped and thus, it remains unknown which haplotypes carry this SNV
Standardization Retired After intronic SNVs were removed, the *1C, *13B and *15B haplotypes were identical to *1B (*1.002), *13A (*13.002) and *15A (*15.001) and thus were retired.
Other Upstream SNVs were removed -1456T>C and -750T>C were removed from *28 because it remained uncertain whether these SNVs are indeed on this haplotype (76) and personal communication with author)